Lumiracoxib
Lumiracoxib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against prostaglandin G/H synthase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | 9 | 2 | — | 11 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | 2 | — | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 2 | — | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | 1 | 1 | — | 2 |
| Healthy volunteers/patients | — | — | — | — | — | — | 1 | — | 1 |
| Controlled hypotension | D007023 | — | — | — | — | — | 1 | — | 1 |
| Musculoskeletal pain | D059352 | — | — | — | — | — | 1 | — | 1 |
| Gouty arthritis | D015210 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | 5 | — | — | 5 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | 1 | — | — | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 1 | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | — | 1 | — | — | — | 1 |
| Arthralgia | D018771 | — | M25.5 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lumiracoxib |
| INN | lumiracoxib |
| Description | Lumiracoxib is an amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity. It has a role as a cyclooxygenase 2 inhibitor and a non-steroidal anti-inflammatory drug. It is an organofluorine compound, an organochlorine compound, an amino acid, a secondary amino compound and a monocarboxylic acid. |
| Classification | Small molecule |
| Drug class | cyclooxygenase-2 inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 220991-20-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL404108 |
| ChEBI ID | 73044 |
| PubChem CID | 151166 |
| DrugBank | DB01283 |
| UNII ID | V91T9204HU (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,040 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
54 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use